Welcome to Celleron Therapeutics

Celleron is building a global oncology company focussed on the clinical development of new and innovative therapies to treat cancer.

Clinical products

Zabinostat

Zabinostat (CXD101) is a novel epigenetic regulator with immune-regulatory properties. It is an orally available small molecule with anti-tumour properties and a well-tolerated safety profile in humans. It allows tumour cells to be recognised by the immune system and has shown efficacy in colorectal cancer and lymphomas.

Emactuzumab

Emactuzumab (CXD301) is a humanised recombinant monoclonal antibody directed against the Colony Stimulating Factor-1 Receptor expressed on tumour-associated M2 macrophages. It effectively depletes CSF-1R positive macrophages in the tumour microenvironment.

Our mission

Celleron is building a global oncology company focussed on the clinical development of new and innovative therapies to treat cancer. Celleron’s vision is that the future of cancer therapy lies in the ability to match therapies to individual patients. We are achieving this precision medicine through our proprietary drugs, biomarkers, events, and trials.

David Kerr, CBE

Read more...